Early detection of triple-negative breast cancer return
Part of Cancer, Skin clinical trials.
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- You had triple-negative breast cancer that had not spread, and you had surgery to remove it 3 to 24 months ago.
- Your tumor was high-risk (for example, it didn't fully respond to chemotherapy before surgery, or it was stage IIB or III).
- You have no signs that your cancer has come back yet.
- You are willing to provide a sample of your stored tumor tissue for testing.
- You have health insurance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a simple blood test (liquid biopsy) and imaging to look for early signs that triple-negative breast cancer has returned after treatment. It is for people who had stage II or III cancer, went through chemotherapy before surgery, and still had cancer left after surgery.
This trial uses a special PET scan (68Ga-FAPI-46) to see if it can predict how well chemotherapy plus immunotherapy (pembrolizumab) works in people with triple-negative breast cancer before surgery. It aims to help doctors understand if the treatment is effective earlier.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.